Immunosuppressive Treatment Articles & Analysis
9 news found
Anders. “A treatment response meeting these proteinuria treatment targets increases the chance for better long-term kidney outcomes such as avoidance of kidney failure, dialysis or need for ...
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the AURA-LV and AURORA 1 studies, also presented at ERA, showed early treatment ...
VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients. ...
(OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis (LN) to the European Medicines Agency (EMA). ...
“Ulcerative Colitis is an increasing burden on society, and a growing disease for which there needs to be improved treatment options. We believe our therapeutic candidate has the potential to provide a much-needed non-immunosuppressant-based treatment option for those suffering with ...
About LUPKYNIS LUPKYNIS™ is the first FDA-approved oral medicine for the treatment of adult patients with active LN. LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the ...
Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with MMF at 1 g twice daily with low-dose oral steroids, for up to an additional 24 months. ...
“The consistent outcomes over time reinforce confidence in LUPKYNIS as an important treatment choice for people experiencing the dangerous manifestation of lupus ...
Published in the June edition of The Lancet Haematology, the results showed the probability of being alive and free of immunosuppressive therapy at 8 years was 47% in the ATLG group and 11% in the non-ATLG[1] group. ...